Combination Vaccines: A New Paradigm in Pediatric Immunization Practices

Study Documents How Price of TNF Inhibitors Rose After New Competition

January 01, 2003

SUPPLEMENT CONTENT

A study of cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after the entry of new competition showed that the newer drugs did not lower costs, and in fact, the annual treatment costs of the existing medicines rose by $17,390. Taxpayer funds shouldered all of the increases, and the “findings illustrate a market failure contributing to the rising costs of prescription drugs,” according to the researchers.